These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16642013)

  • 1. mtDNA clock runs out for dopaminergic neurons.
    Manfredi G
    Nat Genet; 2006 May; 38(5):507-8. PubMed ID: 16642013
    [No Abstract]   [Full Text] [Related]  

  • 2. Detrimental deletions: mitochondria, aging and Parkinson's disease.
    Biskup S; Moore DJ
    Bioessays; 2006 Oct; 28(10):963-7. PubMed ID: 16998822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual dopaminergic neurons show raised iron levels in Parkinson disease.
    Oakley AE; Collingwood JF; Dobson J; Love G; Perrott HR; Edwardson JA; Elstner M; Morris CM
    Neurology; 2007 May; 68(21):1820-5. PubMed ID: 17515544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular mechanisms of dopamine toxicity.
    Barzilai A; Daily D; Zilkha-Falb R; Ziv I; Offen D; Melamed E; Shirvan A
    Adv Neurol; 2003; 91():73-82. PubMed ID: 12442665
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurophysiology: stressful pacemaking.
    Bean BP
    Nature; 2007 Jun; 447(7148):1059-60. PubMed ID: 17597746
    [No Abstract]   [Full Text] [Related]  

  • 6. Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders.
    Gu G; Reyes PE; Golden GT; Woltjer RL; Hulette C; Montine TJ; Zhang J
    J Neuropathol Exp Neurol; 2002 Jul; 61(7):634-9. PubMed ID: 12125742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of activity-dependent mechanisms in the control of dopaminergic neuron survival.
    Michel PP; Alvarez-Fischer D; Guerreiro S; Hild A; Hartmann A; Hirsch EC
    J Neurochem; 2007 Apr; 101(2):289-97. PubMed ID: 17402966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilobalide inhibits 6-OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat substantia nigra.
    Li LY; Zhao XL; Fei XF; Gu ZL; Qin ZH; Liang ZQ
    Acta Pharmacol Sin; 2008 May; 29(5):539-47. PubMed ID: 18430361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons.
    Kraytsberg Y; Kudryavtseva E; McKee AC; Geula C; Kowall NW; Khrapko K
    Nat Genet; 2006 May; 38(5):518-20. PubMed ID: 16604072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine and adult neurogenesis.
    Borta A; Höglinger GU
    J Neurochem; 2007 Feb; 100(3):587-95. PubMed ID: 17101030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glial reactions in Parkinson's disease.
    McGeer PL; McGeer EG
    Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
    Mogi M; Kondo T; Mizuno Y; Nagatsu T
    Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.
    Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K
    J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depigmentation in the nerve cells of the substantia nigra and locus ceruleus in Parkinsonism.
    Forno LS; Alvord EC
    Adv Neurol; 1974; 5():195-202. PubMed ID: 4374062
    [No Abstract]   [Full Text] [Related]  

  • 17. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk.
    Saavedra A; Baltazar G; Santos P; Carvalho CM; Duarte EP
    Neurobiol Dis; 2006 Sep; 23(3):533-42. PubMed ID: 16766196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A channel to neurodegeneration.
    Deutch AY; Winder DG
    Nat Med; 2006 Jan; 12(1):17-8. PubMed ID: 16397545
    [No Abstract]   [Full Text] [Related]  

  • 19. [Morphology and biochemistry of Parkinson's syndrome].
    Jellinger K
    Cesk Patol; 1973 Feb; 9(1):1-13. PubMed ID: 4348906
    [No Abstract]   [Full Text] [Related]  

  • 20. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.